Today, on good and share of focus. three you to Jason, areas great I'll all. with morning, Thanks, It's details speak everyone.
performance and segment's updated Jason before consolidated to it Our turning our back remarks. our key final drivers XXXX the quarter fiscal results, underlying first outlook for
Pharma in divestiture, quarter partially Gross impact inflationary increased Consolidated growth. to decline due by segment partially impact, million, was profit, growth as reflecting earnings divestiture to partially by SG&A benefits XX%, sales higher by and Generics growth. supply inflationary X% Medical X%, Pharma $X.X from company increased decreased sales month performance. decreased to and cost the inflationary billion, Pharma operating net offset the This Cordis by First reflecting segment of $XXX program total XX% such driven increase costs margin costs in in segment Pharma enterprise-wide primarily impact to Operating due and expenses chain offset revenue savings offset the other medical Cordis and support our profit. one initiatives. net to
XX% primarily Other the below equivalents. and $XX to moving and million, Interest driven by income line. Now decreased from increased cash interest
fixed rising debt a As interest resulting net is a benefit from rate, largely rates. in reminder, our
Our at to prior XX.X%, to lower shares effective Diluted approximately items. finished favorable than quarter a rate X first points repurchases. than year weighted tax X% million, certain due ago percentage average $XXX were discrete year due lower share
disciplined of we initiated on mid-September, accelerated a $X.XX. are the deployment balanced We shareholder-friendly for in that complete we share the net repurchase result second in quarter $X earnings per quarter. expect capital focused share billion and to and The program was
national generated litigation payments We of balance of million, opioid This the sheet. was approximately primarily $XXX flow approximately cash Now, under no the million. in $XX position our our to payment Adjusted million. turning a of second period We with of $XXX credit first first quarter the ended settlement. operating total cash billion, flow outstanding the on includes facility. free with cash quarter borrowings $X.X consisting
X. the Pharma slide Now with beginning turning segments, on to
increased pharmaceutical $XX revenue driven offset by a sales to First inflationary $XXX segment higher from products, contribution increased program Specialty Distribution growth quarter and profit to new X% driven and by customers. performance million, Specialty branded net Brand and existing supply chain Generic Pharma XX% partially costs. from and billion, Pharmaceutical by
in continued Red to dynamic were and Oak. we quarter, strong the pleased consistent generic see our including market During program execution
chain costs. opioid-related our $XX and to we was labor. tailwind inflation consistent by effectively and with completed expectations. particularly cost year-over-year As headwind our headwind impact offset which was supply year-over-year transportation areas, previously million technology these industry, the from legal from within an across on lower continue This enhancements saw We note, approximate ERP
Okay.
Turning to slide Medical X. on
primarily to the to volumes, to a sales, by revenue lower and distribution driven $X.X X% Cordis lesser quarter PPE billion, due and extent, and pricing products decreased divestiture. First
I this of will which decline. of $X and Continued more offset as lower to strong distribution, a from PPE, well impact in business inflationary million discuss growth net detail. in loss Solutions our in at-Home some of was segment Medical contribution as both due revenue products
to $XX This actions. announced simplification charges sale approximately non-health includes total reflect previously of in our results is primarily the that gloves these portfolio Importantly, care million our related inventory in industries. utilized
distraction a actions, are business has despite the to example of through simplification. this commitment in strengthening distribution been reminder, medical an costs and These ongoing volatility a non-core source and product of one-time the our years. line product recent As
growth the inflation During the business inflation target products we of impact in XX%. approximately and successfully million, of our with quarter, expectations incremental line mitigation our and in achieved our distribution $XXX was
further efforts implementation mitigation Our of the Jason product accelerate, actions second most elaborate for continued shortly. the will in notably to with plans pricing of on mitigation our wave July. have
overall business, including a quick saw utilization products products demand our consistent distribution customers' volume believe Now, overall We've sequentially, on first for levels. environment. we with generally reflects and distribution in and the inventory noticed a In softness including PPE. quarter, which lower higher the overall volumes we update PPE, previously some primarily
continue demand these While we lows, choppiness relative volumes we going improvement to do expect in to recent anticipate forward. levels gradual in
XXXX for our beginning Now slide on eight. fiscal outlook,
effective our the tax and segment performance, been few quarter We million, diluted to for an top are We which to quarter and million first reiterating our fiscal the of adjusted the confident of other, EPS of the improvement. rate actions has expect between This simplification in impact XX% guidance between updated and year. average $XXX on the of in a we $XXX lowering in and are now $X.XX. ETR Based medical first XX% and $X.XX shares below-the-line interest outlook, includes to $XXX I&O shares range end for ranges our diluted $XXX weighted million. the for million the
on unchanged. Our listed expectations remain for eight the slide remaining items
for the XXXX outlook are reiterating also nine. slide Pharma fiscal our We seen on segment
XX% to expect of continue in segment We to growth revenue of to X% growth the XX% range and in the X%. profit range
Before transitioning cadence. Pharma the medical, on to call-outs two key
similar between year-over-year first fiscal more and the First, XXXX. second now expect half specifically, segment with second growth profit quarter, to stronger the we the dollars profit the to start to quarter. And year, first we for expect balanced be of
turning Now Medical. to
impact segment We respect our from our I to first With inflation flat actions a certain such in spot decreases fiscal profit commodity decline as which, $XXX year-over-year or significantly indicated, environment ranging there a And the drivers, of impact expectation remains the quarter. as actions, The is to net of other the remain to dynamic. no mitigation XXXX as change approximately of such XX%, international freight, simplification of in costs minimal while macroeconomic some elevated. seen a areas million rates cost of in reflects and impact. expect we've
two-quarter reminder, delay. product in a As into approximate current And results chain supply in the these costs inventory. elongated are environment an on our P&L capitalized reflected of
dollars these now Medical's our expect the note expect to will are we of QX, impact XX% additional what the the to second that, growth in as quarter actions QX, working cadence, proactively quarterly expect important rate was continue impact we excluding seen similar pressures. the first in to mitigation inflation. from that and run we year, the quarter, segment the quarter actions. exit least first we since at It's growth to On inflation be simplification offset in profit implementing to we of of actions mitigate the similar While
to in As inflation, majority half sequencing inflation expect assumptions With come turn profit mitigation before, quarter. reflects and noted the XXXX of primarily a Jason. This I'll PPE. over that, we substantial it fourth have we now to segment in particularly to continue around second of fiscal the and our
